Market cap
$84 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-27 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
0.8
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
2,759,220
10 Years Aggregate
CFO
$-340.03 Mln
EBITDA
$-409.96 Mln
Net Profit
$-396.43 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neovasc - ADR
| 90.1 | 2.4 | 7.6 | 217.9 | -22.3 | -52.7 | -53.0 |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Neovasc - ADR
| -50.6 | -82.4 | -10.3 | -99.0 | -65.3 | -61.6 | -34.0 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Neovasc - ADR
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include Tiara for the transcatheter treatment of mitral valve disease; and the... Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. As of April 11, 2023, Neovasc Inc. operates as a subsidiary of Shockwave Medical, Inc. Read more
-
Pres, CEO & Director
Mr. Fredericus A. Colen
-
Pres, CEO & Director
Mr. Fredericus A. Colen
-
Headquarters
Richmond, BC
-
Website
FAQs for Neovasc - ADR
What is the current share price of Neovasc Inc - ADR Today?
The share price of Neovasc Inc - ADR is $30.03 (NASDAQ) as of 19-Apr-2023 09:30 EDT. Neovasc Inc - ADR has given a return of -22.29% in the last 3 years.
What is the current PB & PE ratio of Neovasc Inc - ADR?
Since, TTM earnings of Neovasc Inc - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-- |
-- |
2021 |
-0.06 |
0.03 |
2020 |
-0.03 |
0.48 |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of Neovasc Inc - ADR?
The 52-week high and low of Neovasc Inc - ADR are Rs -- and Rs -- as of 29-Aug-2026.
What is the market cap of Neovasc Inc - ADR?
Neovasc Inc - ADR has a market capitalisation of $ 84 Mln as on 20-Apr-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Neovasc Inc - ADR?
Before investing in Neovasc Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.